

Results reported

April 1, 2026

6,976 patient-participants have received results* from the Genomic Screening and Counseling Program





For the latest results, see geisinger.org/MyCode-results.

350,000+ participants have made the success of MyCode possible

Summary of results reported by category

	Total	Percentage
Cardiovascular risk	3,146	44%
Cancer risk	2,684	38%
Other**	1,244	18%

Breakdown of results reported

Risk Condition 	Patients per condition 	Gene 	Patients per gene 
Cardiovascular risk			
Familial hypercholesterolemia[§] (early heart attacks and strokes)	878	APOB	285
		LDLR	593
Hereditary transthyretin amyloidosis (buildup of amyloid in the body, can lead to heart and nervous system disease)	267	TTR	267
Heritable thoracic aortic disease (genetic predisposition to weakening of the wall of the aorta, leading to swelling and sometimes rupture)	62	ACTA2	62
Inherited arrhythmias (irregular heartbeat with risk for cardiac arrest)	514	KCNH2	58
		KCNQ1	288
		RYR2	1
		SCN5A	167

(continued on next page)

MyCode® results reported (continued)





6,976 patient-participants have received results*
from the Genomic Screening and Counseling Program

Risk Condition	Patients per condition	Gene	Patients per gene
Cardiovascular risk <small>(continued)</small>			
Inherited cardiomyopathies (diseases of the heart muscle with dangerous complications)	1,422	BAG3	3
		DSC2	66
		DSG2	81
		DSP	111
		FLNC	71
		LMNA	30
		MYBPC3	269
		MYH7	107
		MYL2	11
		MYL3	8
		PKP2	108
		PRKAG2	3
		RBM20	1
		TNNI3	40
		TNNT2	10
TPM1	6		
TTN	497		
Cancer risk			
Familial adenomatous polyposis (intestinal polyps and early colon cancer)	82	APC	82
Hereditary breast and ovarian cancer[§] (early breast, ovarian, prostate, pancreatic and other cancers)	1,294	BRCA1	458
		BRCA2	836
Hereditary pheochromocytomas and paragangliomas (tumors that can release extra hormones and, rarely, become cancer)	159	SDHAF2	15
		SDHB	71
		SDHC	26
		SDHD	13
		TMEM127	34
Li-Fraumeni syndrome (early breast, soft tissue, brain, adrenal and other cancers)	30	TP53	30

(continued on next page)

MyCode® results reported (continued)





6,976 patient-participants have received results*
from the Genomic Screening and Counseling Program

Risk Condition 	Patients per condition 	Gene 	Patients per gene 
Cancer risk <small>(continued)</small>			
Lynch syndrome[§] (early colon, uterine and other cancers)	713	MLH1 MSH2 MSH6 PMS2	63 51 311 288
Multiple endocrine neoplasia type 1 (tumors that can release extra hormones and, rarely, become cancer)	26	MEN1	26
Multiple endocrine neoplasia type 2 (early thyroid cancer)	149	RET	149
MUTYH-associated polyposis (intestinal polyps and early colon cancer)	9	MUTYH	9
Neurofibromatosis, type 2 (noncancerous tumors in nervous system)	1	NF2	1
PALB2-related cancer risk (early onset breast, pancreatic, and ovarian cancers)	203	PALB2	203
Peutz-Jeghers syndrome (early breast, colon, pancreatic and other cancers)	2	STK11	2
Retinoblastoma (early eye cancer)	9	RB1	9
Von Hippel-Lindau syndrome (early kidney cancer and benign tumors of the brain, eye, pancreas and adrenal gland)	4	VHL	4
Wilms tumor (malignant kidney tumor)	3	WT1	3
Miscellaneous phenotypes			
Biotinidase deficiency (buildup of a B vitamin in the body, can cause issues with the nervous system)	3	BTD	3
Fabry disease (enzyme defect leading to damage of blood vessels in the skin and cells in the kidneys, heart, and nervous system)	14	GLA	14

(continued on next page)

MyCode® results reported (continued)





6,976 patient-participants have received results*
from the Genomic Screening and Counseling Program

Risk Condition 	Patients per condition 	Gene 	Patients per gene 	
Miscellaneous phenotypes <small>(continued)</small>				
Hereditary hemochromatosis	648	HFE	648	
(too much iron in blood, can lead to liver and heart problems)				
Hereditary hemorrhagic telangiectasia	61	ACVRL1	18	
(abnormal blood vessel formation in skin, mucous membranes, lungs, liver and brain)			ENG	43
Juvenile polyposis	5	BMPR1A	5	
(intestinal polyps, cancer of the intestine, including colon)				
Juvenile polyposis / hereditary hemorrhagic telangiectasia	6	SMAD4	6	
(intestinal polyps, cancer of the intestine, including colon/abnormal blood vessel formation in skin, mucous membranes, lungs, liver & brain)				
Loeys-Dietz syndrome	16	SMAD3	10	
(weakening of the wall of the aorta, leading to swelling and sometimes rupture)			TGFB1	2
			TGFB2	4
Malignant hyperthermia	317	RYR1	309	
(life-threatening condition usually triggered by exposure to certain drugs used for general anesthesia)			CACNA1S	2
Marfan syndrome	39	FBN1	39	
(connective tissue disease that can cause heart, eye, and skeletal problems)				
Maturity-onset diabetes of the young (MODY)	17	HNF1A	17	
(Diabetes in the teens or early adulthood)				
Ornithine transcarbamylase deficiency	4	OTC	4	
(buildup of ammonia in the blood, can cause altered mental status and seizures)				
Pompe disease	20	GAA	20	
(buildup of glycogen which could cause muscle problems throughout the body)				
PTEN hamartoma tumor syndrome	26	PTEN	26	
(early breast, thyroid, uterine and other cancers, with intellectual disability in some cases)				

(continued on next page)

MyCode® results reported (continued)

6,976 patient-participants have received results*
from the Genomic Screening and Counseling Program

Risk Condition 	Patients per condition 	Gene 	Patients per gene 
Miscellaneous phenotypes <small>(continued)</small>			
Retinopathy (gradual vision loss, can lead to blindness)	1	RPE65	1
Tuberous sclerosis (multiple types of benign tumors)	33	TSC1	9
		TSC2	24
Vascular Ehlers-Danlos syndrome (disease of the connective tissues, including arteries and muscles, that can increase the risk for health complications, such as rupture of arteries)	17	COL3A1	17
Wilson disease (too much copper in the body, can cause liver disease and nervous system issues)	12	ATP7B	12

Totals^{†,‡}

7,074



7,074

[§]CDC Tier 1 Condition

*Number of patient-participants with reported results and the number per gene variant/condition may not be equal due to the possibility of a participant having more than one result.

** Other - Includes conditions with metabolic presentation or syndromic cancer or cardiovascular risk

[†]Includes some patients (~12%) already aware of their genomic result from clinical genetic testing. The process of clinical confirmation and disclosure may be modified for these patients

[‡]The gene list designated for return has shifted over time (PMID: 33576083). Totals include fewer than 10 results in genes no longer on the return list.